Bariatric surgery has more powerful long-term effects on controlling type 2 diabetes mellitus (T2DM) that medical therapy alone, according to the largest, long-term study comparing methods.
Bariatric surgery has more powerful long-term effects on controlling type 2 diabetes mellitus (T2DM) than medical therapy alone, according to the largest, long-term study comparing methods.1
Results of the Cleveland Clinic’s STAMPEDE study were shared at Monday’s late-breaking session of the 63rd Scientific Sessions of the American College of Cardiology, which concluded in Washington, DC. The results were simultaneously published in The New England Journal of Medicine,1 and the study’s presenter, Sangeeta Kashyap, MD, answered questions immediately afterward at a press briefing.
Dr Kashyap captured headlines in February 20132 when she published a substudy of STAMPEDE in Diabetes Care,3 the journal of the American Diabetes Association (ADA). In that article, Dr Kashyap outlined the mechanism by which bariatric surgery, which has been used primarily to help obese patients lose large amounts of weight, has helped patients overcome their T2DM status within days, long before they shed the pounds.
As she explained at the time, “A gastric bypass changes hormones in the gut, which triggers the pancreas to start making insulin again.”2
Researchers at the Cleveland Clinic designed STAMPEDE, which stands for Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently, to assemble evidence that might make surgery an acceptable alternative to medication in combating T2DM, which affects 25 million Americans; an estimated 79 million also have prediabetes, according to the ADA.4
Results presented Monday involved 150 patients, age 41 to 57 years, who received 1 of 3 treatment options: intensive medical therapy that included lifestyle changes and counseling along with medication; medical therapy plus Roux-en-Y gastric bypass; or medical therapy plus sleeve gastrectomy. Almost all of the patients, 91.3%, remained in the study at the 3-year mark.
At the start of the study, the average glycated hemoglobin (A1C) level for all patients was 9.2%. Most patients had been living with the disease at least 8 years and were taking at least 3 antidiabetic medications. All were overweight, although some patients had a body mass index as low as 27 kg/m2, which might not make them a candidate for bariatric surgery without T2DM. Women made up 66% of the study group.
All 3 groups saw a drop in A1C levels at the 6-month mark; however, the groups receiving surgery were largely able to sustain the declines over 3 years, while the group receiving only medical therapy experienced a gradual rise to levels approaching preintervention rates. Results were:
At the 3-year mark, weight loss was 5 to 6 times greater for patients who received gastric bypass or sleeve surgery compared with those receiving medical therapy only. Average loss for the gastric bypass group was 24%; average loss for the sleeve group was 21%; while average loss for the medical therapy only group was just 4%.5
Researchers acknowledge that these surgical procedures are not without risks, which they listed as bleeding, infection, or blood clots. The study team reported that the most common issues at 12 months were short-term dehydration, bleeding, and 1 leak. Four of the 100 surgical patients needed an additional surgery for complications within the first year.
One issue that was not reported came up in response to a question from The American Journal of Managed Care. Dr Kashyap was asked if investigators observed the phenomenon, reported in the literature since 2012, that some gastric bypass patients experience alcohol abuse in year 2 after surgery. This topic was explored in a recent issue of Evidence-Based Diabetes Management.5
Dr Kashyap said that “2 or 3” patients experienced alcohol abuse, but that it turned out that those patients had had some history of substance abuse issues. When asked why these incidents were not reported as adverse events, Dr Kashyap said it was due to the patients’ histories.
In her presentation, Dr Kashyap emphasized that surgical patients outscored the medical therapy group on quality-of-life tests; when asked about this at the late-breaking session, she said that the weight loss gave patients confidence, and that for patients who no longer had needed insulin injections, quality of life improved enormously.
The lead author on the study, Philip Schauer, MD, said endocrinologists were interested in the phenomenon, but without long-term results, most were unwilling to consider surgery as a therapy alongside traditional pharmacological-based therapies and lifestyle modifications. “Now the evidence is mounting, and we see the benefits of surgery over medical therapy for these patients,” he said in a statement.6
REFERENCES
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More